Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASCO
Biotech
ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC
The companies plan to submit the EGFR tyrosine kinase inhibitor for an FDA approval during the second half of this year.
Gabrielle Masson
May 22, 2025 5:00pm
Pfizer shares prostate cancer data after leak, inks Alloy deal
Feb 11, 2025 1:07pm
ASCO: It's back to the basics for cancer drug developers
Jun 5, 2024 10:55am
AbbVie rebuilds ADC portfolio with hope of replacing chemotherapy
Jun 4, 2024 11:26am
Merck's 3-pronged cancer plan stars Moderna-partnered vaccine
Jun 3, 2024 8:00am
'The Top Line': The year in biotech
Dec 22, 2023 7:00am
